



(12) **United States Patent**
Klaerner et al.

(10) **Patent No.:** **US 9,925,212 B2**
(45) **Date of Patent:** **Mar. 27, 2018**

(54) **POTASSIUM-BINDING AGENTS FOR
TREATING HYPERTENSION AND
HYPERKALEMIA**

(71) Applicant: **Relypsa, Inc.**, Redwood City, CA (US)

(72) Inventors: **Gerrit Klaerner**, Hillsborough, CA
(US); **Lance Berman**, San Francisco,
CA (US)

(73) Assignee: **Relypsa, Inc.**, Redwood City, CA (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/287,179**

(22) Filed: **Oct. 6, 2016**

(65) **Prior Publication Data**
US 2017/0020916 A1 Jan. 26, 2017

Related U.S. Application Data

(63) Continuation of application No. 14/581,698, filed on
Dec. 23, 2014, now Pat. No. 9,492,476, which is a
(Continued)

(51) **Int. Cl.**
A61K 9/00 (2006.01)
A61K 31/78 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC **A61K 31/78** (2013.01); **A61K 9/14**
(2013.01); **A61K 31/7004** (2013.01);
(Continued)

(58) **Field of Classification Search**
CPC **A61K 31/78**
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,340,111 A 1/1944 D'Alelio
2,611,730 A 9/1952 Heming
(Continued)

FOREIGN PATENT DOCUMENTS

EP 0349453 A1 1/1990
EP 0730494 A1 9/1996
(Continued)

OTHER PUBLICATIONS

Chernin, Secondary Prevention of Hyperkalemia with Sodium
Polystyrene Sulfonate in Cardiac and Kidney Patients on Renin-
Angiotensin-Aldosterone System Inhibition Therapy, Clin. Cardiol.
35(1), 2012, 32-36.*

(Continued)

Primary Examiner — Paul Dickinson

(74) *Attorney, Agent, or Firm* — Senniger Powers LLP

(57) **ABSTRACT**

The present invention generally relates to methods of treat-
ing hypertension (HTN) in patients in need thereof wherein
the patient optionally further suffers from chronic kidney
disease (CKD) or Type II diabetes mellitus (T2DM). The
invention also relates to methods of treating hyperkalemia in
a patient in need thereof, wherein the patient suffers from
CKD, T2DM or HTN and are optionally being treated with
an effective amount of a renin-angiotensin-aldosterone sys-
tem (RAAS) agent. The invention also relates to methods of
treating kidney disease in a patient in need thereof, wherein
the patient is optionally being treated with an effective
amount of a renin-angiotensin-aldosterone system (RAAS)
agent. The methods can comprise administering an effective
amount of a potassium-binding agent to the patient to lower
the patient's blood pressure and/or increase or stabilize the
patient's kidney function.

25 Claims, 5 Drawing Sheets

